Rezolute

RZLT

時価総額 $3.46億

Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities

U.S. stocks settled higher on Friday, with the Dow Jones index recording sharp gains during the session as crude oil retreated on hopes for an Iran-brokered reopening of the Strait of Hormuz.

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.

Data from the Phase 3 sunRIZE study remains under review by FDA  The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today provided an update on the status of the ongoing U.S. Food and Drug Administration (“FDA” or “Agency”) review of data from the Company's Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI.

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenital HI and a case series from its Expanded Access Program (EAP) in tumor HI REDWOOD CITY, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today highlighted four data presentations delivered at the Annual Meeting of the Endocrine Society (ENDO).

Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced four presentations at the upcoming Annual Meeting of the Endocrine Society (ENDO) being held June 13-16, 2026, in Chicago, IL.